Home > Healthcare > Biotechnology > Biotechnology R&D > Preimplantation Genetic Testing (PGT) Market

Preimplantation Genetic Testing (PGT) Market Trends

Report ID: GMI12034
Published Date: Oct 2024
Report Format: PDF

Download Free Sample

Preimplantation Genetic Testing Market Trends

Growing advancements in PGT technologies significantly propel market demand by enhancing the accuracy, efficiency, and accessibility of genetic screening. Innovations such as next generation sequencing (NGS), allow for comprehensive analysis of embryos, enabling the detection of chromosomal abnormalities and specific genetic disorders with greater precision.

For instance, in July 2023, Thermo Fisher Scientific launched two new NGS-based research tools, the Ion ReproSeq PGT-A Kit and the Ion AmpliSeq Polyploidy Kit, designed for PGT for aneuploidy (PGT-A). These tools were intended to enhance genetic screening in IVF and intracytoplasmic sperm injection (ICSI) procedures. This launch strengthens the company's offering and position in the reproductive health research market and supports advancements in genetic testing for healthier pregnancies.

Further, advancements in non-invasive PGT techniques transformed ART that aimed to significantly improve the safety and precision of genetic testing in IVF. A breakthrough involves analyzing cell-free DNA (cfDNA) from blastocoel fluid or embryo culture media, eliminating the need for invasive embryo biopsies. These innovations drive the adoption of PGT, further propelling market expansion as more individuals seek advanced reproductive testing.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global preimplantation genetic testing industry was valued at USD 780.8 million in 2023 and is estimated to grow at a 9.4% CAGR from 2024 to 2032, driven by the increasing prevalence of genetic disorders in newborns and rising awareness of reproductive health.

The product segment dominated the market and is anticipated to grow at a 9.3% CAGR over the forecast period, as it includes essential reagents, sequencing kits, and testing consumables required for accurate embryo testing in IVF procedures.

U.S. accounted for USD 312.2 million in the North American preimplantation genetic testing industry in 2023 and is expected to maintain its dominance throughout the forecast period, attributed to the widespread adoption of advanced reproductive technologies and growing awareness of genetic screening.

Key players in the industry include Agilent Technologies, Fulgent Genetics, Genea BIOMEDX, Illumina, Medicover Genetics, Natera, and Revvity.